<DOC>
	<DOCNO>NCT00333723</DOCNO>
	<brief_summary>This study design evaluate safety efficacy AVANDIA ( rosiglitazone ) ( 8mg daily ) African American Hispanic patient type 2 diabetes mellitus . As microvascular macrovascular disease significant contributor diabetes morbidity mortality previous study suggest thiazolidinedione compound could potentially beneficial vascular effect , effect rosiglitazone therapy serum parameter associate endothelial dysfunction , vascular inflammation impair fibrinolysis examine study . Improvement parameter suggest rosiglitazone may provide additional beneficial vascular effect , apart ability improve glycemic control .</brief_summary>
	<brief_title>AVANDIA With Glyburide In African American And Hispanic Patients With Type 2 Diabetes Not Controlled Glyburide Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Inclusion criterion : African American Hispanic . Type 2 diabetes mellitus . FPG &gt; =140mg/dL plus HbA1c &gt; =7.5 % whilst receive SU monotherapy . Exclusion criterion : Patients use insulin . Clinically significant liver , kidney heart disease , include high blood pressure .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Rosiglitazone</keyword>
	<keyword>Glyburide</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>African American</keyword>
	<keyword>Hispanic</keyword>
</DOC>